Location Directory

Clinical trials in New Haven, Connecticut

This page shows live ClinicalTrials.gov search results for New Haven, Connecticut, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:24 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1352

Shown on this page

Current sort

Institutions in New Haven

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Yale

Live official records

Open in full search

Conditions: Nonmetastatic Castration-Resistant Prostate Cancer, Prostate Cancer, Cancer of the Prostate
Interventions: Enzalutamide, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,401 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2025
U.S. locations: 37
States / cities: Tucson, Arizona • Los Angeles, California • Orange, California + 27 more

Conditions: Type 2 Diabetes
Interventions: Ultrasound Delivery; Device
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, B-cell Lymphoma, Small Lymphocytic Lymphoma
Interventions: Pirtobrutinib, Venetoclax, Rituximab; Drug
Lead sponsor: Loxo Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 803 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 31
States / cities: Scottsdale, Arizona • San Diego, California • San Francisco, California + 25 more

Conditions: Cardiac Arrest (CA), Hypoxic-Ischemic Brain Injury
Interventions: portable MRI scanner; Device
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Opioid Use Disorder, Clinical Decision Support
Interventions: Nurse prompt, Provider prompt, Patient facing materials, EMBED; Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 1,129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 3
States / cities: Guilford, Connecticut • New Haven, Connecticut

Conditions: Fecal Microbiota Transplantation, Clostridium Difficile Infection, Gut Microbiome
Interventions: None - Observational; Other
Lead sponsor: American Gastroenterological Association; Other
Eligibility: Not listed
Enrollment: 4,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 52
States / cities: Phoenix, Arizona • Los Angeles, California • Redwood City, California + 39 more

Conditions: Hypertension
Interventions: Placebo, lorundrostat Dose 1, lorundrostat Dose 2; Drug
Lead sponsor: Mineralys Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 104
States / cities: Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 88 more

Conditions: Pelvic Floor Disorder, Pelvic Floor Muscle Exercise
Interventions: Pelvic Floor Muscle Therapy Website; Device
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Symptomatic Aortic Stenosis
Interventions: Evolut™ PRO and Evolut™ PRO+ System (Evolut™ FX System for the addendum); Device
Lead sponsor: Medtronic Cardiovascular; Industry
Eligibility: Not listed
Enrollment: 1,127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 37
States / cities: Birmingham, Alabama • San Francisco, California • Hartford, Connecticut + 32 more

Conditions: Stage III Distal Bile Duct Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Distal Bile Duct Cancer AJCC v8, Stage IIIA Gallbladder Cancer AJCC v8, Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIB Distal Bile Duct Cancer AJCC v8, Stage IIIB Gallbladder Cancer AJCC v8, Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Gallbladder Cancer AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Stage IVA Gallbladder Cancer AJCC v8, Stage IVB Gallbladder Cancer AJCC v8, Unresectable Extrahepatic Bile Duct Carcinoma, Unresectable Gallbladder Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Cisplatin, Gemcitabine Hydrochloride, Nab-paclitaxel; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 692
States / cities: Anchorage, Alaska • Goodyear, Arizona • Kingman, Arizona + 448 more

Conditions: Failed or Difficult Intubation, Sequela, Intubation; Difficult, Intubation Complication
Interventions: Not listed
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Not listed
Enrollment: 150,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2030
U.S. locations: 63
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 50 more

Conditions: Ureteral Cancer, Urothelial Cancer, Bladder Cancer
Interventions: Enfortumab Vedotin, Docetaxel, Vinflunine, Paclitaxel; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 608 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 25
States / cities: Orange, California • Sacramento, California • Whittier, California + 21 more

Clinical trials in New Haven, Connecticut

Filter and sort this location

Institutions in New Haven

Live official records

Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

Ultrasound Effects on Glycemic Control in T2DM

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

Identification of Brain Injury Using Portable MRI

Adaptive Decision Support for Addiction Treatment (ADAPT) Factorial Trial

Fecal Microbiota Transplant National Registry

A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen

Video-Based Pelvic Floor Muscle Therapy

Optimize PRO Study

Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers

Improving Safety and Quality of Tracheal Intubation Practice in Pediatric ICUs

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)